Cardiovascular Endorsement Maintenance Steering Committee April 7-8, 2011

Venable Conference Center The Capital Room 575 7th Street, NW Washington, DC 20005

Please use the following information to access the conference call line: Participant Dial-in Number: 1-888-515-2880 Conference ID: 6515352

DRAFT AGENDA

Day 1 – April 7

8:00 am	Continental Breakfast
8:30 am	Welcome and Introductions
	Helen Burstin, MD, MPH Senior Vice President of Performance Measures
	Ray Gibbons, MD (Chair)
	Mary George, MD, MSPH (Vice-Chair)
	Reva Winkler, MD, MPH, Senior Program Director
	Ashley Morsell, MPH, Project Manager
	Kathryn Streeter, MS, Project Manager
	Disclosures of Interest
	Ann Hammersmith, General Counsel
8:45 am	Project Status Update
	Dr. Winkler
	Ms. Morsell
	Ms. Streeter
9:00 am	Consideration of Candidate Measures:
	Atrial fibrillation
	Brief Introduction of Measures by Developers
	• 1524 Assessment of Thromboembolic Risk (PCPI)
	• 1525 Chronic anticoagulation therapy (PCPI)
	• 1505 Adult patients with atrial fibrillation taking amiodarone that had serum
	ALT or AST test in last reported 12 months (Ingenix)
10.00	

10:00 am Break

10:30 am **Consideration of Candidate Measures:**

ICD Implants

Brief Introduction of Measures by Developers

- 1530 Prophylactic antibiotics prior to ICD (lead or implant) procedure (ACCF)
- 1522 ACE/ARB Therapy at Discharge for ICD implant patients with LVSD (ACCF)
- 1528 Beta blocker at discharge for ICD implant patients with a previous MI (ACCF)
- 1529 Beta blocker at discharge for ICD implant patients with LVSD (ACCF)
- 0965 Therapy with ACE/ARB and beta blocker at discharge following ICD implantation (ACCF)

12:20 pm NQF Member/Public Comment

- 12:00 pm Lunch Break
- 1:00 pmConsideration of Candidate Measures
Brief Introduction of Measures by Developer
Percutaneous Coronary Interventions (PCI)
 - 0964 Therapy with aspirin, P2Y12 inhibitor and statin at discharge

1:20 pm <u>Hypertension</u>

Brief Introduction of Measures by Developers

- 0018 Controlling high blood pressure (NCQA)
- 0013 Hypertension: Blood Pressure Control (PCPI/ACC)
- 0276 Hypertension (PQI 7) (AHRQ)

2:20 pm <u>Heart Failure - Hospital</u> Brief Introduction of Measures by Developers

- 0135 Evaluation of left ventricular systolic dysfunction (CMS)
- 0162 ACEI or ARB for left ventricular (CMS)
- 0136 Heart failure: Detailed Discharge instructions (CMS)

3:20 pm ET Break

- 3:30 pmConsideration of Candidate Measures
Heart Failure Hospital (con't)
Brief Introduction of Measures by Developers
 - 0358 Heart failure in-patient mortality (AHRQ)
 - 0277 CHF admission (PQI 8) (AHRQ)

- 0229 Hospital 30-day, all-cause, risk standardized mortality rate (RSMR) following heart failure hospitalization (CMS)
- 0330 30-day, all-cause risk standardized readmission rate following heart failure hospitalization (risk adjusted) (CMS)
- 962 Composite Measure of Hospital Quality for Heart Failure (CMS)
- 5:30 pm NQF Member/Public Comment
- 5:45 pm Adjourn

<u>Day 2 – April 8</u>

8:00 am	Welcome, Recap of Day One
	Dr. Gibbons
	Dr. George
8:10 am	Consideration of Candidate Measures
	Heart Failure (outpatient)
	Brief Introduction of Measures by Developers
	• 0077 Heart Failure: Symptom and Activity Assessment (PCPI)
	• 0079 Heart Failure: Left Ventricular Ejection Fraction Assessment (outpatient setting) (PCPI)
	• 0081 Heart Failure: ACEI or ARB therapy for left ventricular systolic dysfunction (PCPI)
	• 0083 Heart Failure: Beta-blocker therapy for left ventricular systolic dysfunction (PCPI)
9:30 am	Follow-up from Phase I
	Retirement of Measures
	Disparities data
10:00 am	Competing and Related Measures – Phases I and II
10:45 am	Break
11:50 pm	NQF Member/Public Comment
12:00 pm	Lunch break
12:30 pm	Competing and Related Measures (con't)
2:00 pm	Review of measures recommended for endorsement

Gaps in Cardiovascular Measures Additional recommendations

- 2:30 pm NQF Member/Public Comment
- 2:45 pm Next Steps/Timeline for Project
- 3:00 pm Adjourn